Tech Company Financing Transactions
Trefoil Therapeutics Funding Round
Trefoil Therapeutics, based in San Diego, raised $28 million in funding from Bios Partners, AJU IB Investment and Correlation Ventures.
Transaction Overview
Company Name
Announced On
7/17/2019
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series A
Investors
Bios Partners (Lead Investor) (Stella Robertson)
Proceeds Purpose
This funding supports the completion of a Phase 2a proof-of-concept study in corneal endothelial dystrophy, including Fuchs dystrophy, a disease which leads to the deterioration of the endothelial layer on the back surface of the cornea.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11189 Sorrento Valley Rd. 104
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Trefoil was founded to bring forward novel engineered FGF-1 (eFGF-1) compounds to treat dorneal diseases adn disorders. Lead candidate TTHX1114 is an engineered form of FGF-1 designed to protect corneal endothelial cells and restore vision loss by stimulating cell proliferation and migration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Benjamin McGraw
Chief Executive Officer
David Eveleth
VP - Bus. Development
Schalon Newton
Browse more venture capital transactions:
Prev: 7/17/2019: Finix Payments venture capital transaction
Next: 7/17/2019: Bitwise Asset Management venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs